TherapeuticsMD Inc (TXMD)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$2.21-1.34%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Intact: The reason to own it still holds.
TherapeuticsMD is growing revenue from $393K to $724K in one year. Operating losses are shrinking from $1.28M to $723K. Net income improved from a loss of $653K to a gain of $95K. The company keeps positive cash flow from operations near $944K.
The company remains small with high risk and expensive valuation. Profit gains are small and may stall. Market pullbacks could pressure cash flow and growth. Legal and accounting changes add uncertainty.
The price is about 20% above our fair value near $1.66. The market expects moderate growth but the company’s small scale and risks may limit upside. Our view is cautious given the high valuation and mixed signals.
Breaks if: net income falls below -$653,000 next year
Focus on improving net income from losses to positive results over time.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround opportunity with a medium confidence level. The company has made progress in improving its financial performance, yet it remains in a watch state due to potential volatility in the healthcare sector.
The current valuation reflects a low level of fragility, suggesting the market does not fully account for potential execution risks. TXMD trades at a premium compared to its peers, indicating some expectations for future performance improvements.
Management is focused on increasing revenue and improving profitability, which has shown positive trends in recent quarters. However, there is a significant near-term risk of missing earnings expectations, which could impact investor sentiment.
The long-term thesis hinges on the performance of sector bellwethers and the overall health of the healthcare sector. If these companies continue to perform well, it could provide a favorable environment for TXMD.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 5 of last 5 quarters. Net income improved from a loss of $653,000 in 2025-Q1 to a positive $95,000 in 2026-Q1, showing progress toward profitability. The trajectory is delivering improvement in net income.
“Net income was $95,000.”
“Net loss was $619,000.”
“Net income was $152,000.”
“Net income was $551,000.”
“Net loss was $653,000.”
Breaks if: operating loss worsens beyond -$1.28M next year
Focus on growing revenue while reducing operating losses to achieve profitability.
Stated as a priority in 5 of last 5 quarters. Revenue grew from $393,000 in 2025-Q1 to $724,000 in 2026-Q1, while operating losses improved from $1,281,000 to $723,000 over the same period. The trajectory shows delivering progress on revenue growth and reducing operating losses.
“Revenue was $724,000 with operating loss of $723,000.”
“Revenue was $893,000 with operating loss of $1,552,000.”
“Revenue was $784,000 with operating loss of $862,000.”
“Revenue was $952,000 with operating loss of $695,000.”
“Revenue was $393,000 with operating loss of $1,281,000.”
Breaks if: operating cash flow falls below $375,000 next year
Sustain positive cash flow from operating activities to support ongoing operations and financial stability.
Stated as a priority in 5 of last 5 quarters. Cash from operating activities remained positive each quarter, ranging from $375,000 in 2025-Q4 to $999,000 in 2025-Q3, and was $944,000 in 2026-Q1. The company is delivering consistent positive cash flow from operations.
“Cash from operating activities was $944,000.”
“Cash from operating activities was $375,000.”
“Cash from operating activities was $999,000.”
“Cash from operating activities was $381,000.”
“Cash from operating activities was $699,000.”
Breaks if: revenue falls below $393,000 next year
Focus on growing revenue while reducing operating losses to achieve profitability.
Stated as a priority in 5 of last 5 quarters. Revenue grew from $393,000 in 2025-Q1 to $724,000 in 2026-Q1, while operating losses improved from $1,281,000 to $723,000 over the same period. The trajectory shows delivering progress on revenue growth and reducing operating losses.
“Revenue was $724,000 with operating loss of $723,000.”
“Revenue was $893,000 with operating loss of $1,552,000.”
“Revenue was $784,000 with operating loss of $862,000.”
“Revenue was $952,000 with operating loss of $695,000.”
“Revenue was $393,000 with operating loss of $1,281,000.”
Overall, TXMD is on a recovery path but remains sensitive to external market conditions. Not investment advice.